Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
While low-volatility stocks promise stability in turbulent markets, experts warn that their defensive appeal may mask underlying risks and missed opportunities for growth. We examine three such companies that investors might want to approach with caution.
While low-volatility stocks can anchor a portfolio, investors often sacrifice growth for stability. We analyze three such stocks, identifying one with resilient fundamentals and two where caution may be warranted.
While market darlings come and go, a select group of companies achieves sustained outperformance through a powerful trifecta: rising sales, expanding profitability, and efficient capital use. We examine three such names that have delivered triple-digit returns over the past five years.
Royal Caribbean Group (RCL) reported strong fourth-quarter results, meeting revenue expectations with a 13.3% year-over-year increase to $4.26 billion. The cruise giant's performance, driven by record passenger volumes and strategic investments, signals robust health in the leisure travel sector.
Cullen/Frost Bankers (NYSE: CFR) reported robust fourth-quarter results, beating analyst estimates on earnings and revenue. The Texas-based regional bank also announced a new $300 million share repurchase program and raised its guidance, fueling a debate on whether its current valuation fully reflects its growth trajectory.
Atlassian confronts a mounting identity theft campaign targeting its systems while rival Anthropic launches a competing AI collaboration tool, adding pressure to a stock already down over 50% in the past year.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
A coalition of immigrant advocacy organizations has filed a federal lawsuit challenging a newly revealed ICE policy that permits agents to enter private residences without judicial warrants, arguing it violates constitutional protections against unreasonable searches.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze three market leaders, identifying one with compelling potential and two where the current story may be fully priced in.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
Usama Ghanem, an Egyptian student at King's College London, faces imminent deportation after disciplinary action linked to his pro-Palestinian activism. He claims the university's response mirrors the political persecution he fled in Egypt, raising urgent questions about academic freedom and the treatment of international dissent.
Facing ongoing labor disputes, Starbucks unveils a massive investment in new espresso machines, AI-assisted POS systems, and a store rating program aimed at streamlining operations and improving the partner experience.
Gold and silver prices experienced a dramatic sell-off following President Trump's surprise nomination of former Fed governor Kevin Warsh to chair the Federal Reserve, sparking intense debate over future monetary policy direction.
Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
France's maritime authority reports rescuing over 6,000 migrants from the English Channel last year, with at least 25 fatalities. Despite the peril, crossings persist at high volume, fueled by increasingly overcrowded boats and evolving smuggling methods.
